📣 VC round data is live. Check it out!

Sofwave Medical Valuation Multiples

Discover revenue and EBITDA valuation multiples for Sofwave Medical and similar public comparables like NeuroPace, Japan Lifeline, Tactile Medical, Bioventus and more.

Sofwave Medical Overview

About Sofwave Medical

Sofwave Medical Ltd is engaged in the development, marketing, and production of non-invasive technology for skin rejuvenation and firming treatment.


Founded

N/A

HQ

Israel

Employees

N/A

Financials (FY)

Revenue: $88M
EBITDA: $8M

EV

$523M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Sofwave Medical Financials

Sofwave Medical reported last fiscal year revenue of $88M and EBITDA of $8M.

In the same fiscal year, Sofwave Medical generated $66M in gross profit, $8M in EBITDA, and $5M in net income.


Sofwave Medical P&L

In the most recent fiscal year, Sofwave Medical reported revenue of $88M and EBITDA of $8M.

Sofwave Medical is profitable as of last fiscal year, with gross margin of 75%, EBITDA margin of 9%, and net margin of 6%.

See analyst estimates for Sofwave Medical
Last FY202320242025202620272028
Revenue$88M$50M$60M$88M
Gross Profit$66M$37M$45M$66M
Gross Margin75%74%76%75%
EBITDA$8M($7M)($2M)$8M
EBITDA Margin9%(13%)(4%)9%
EBIT Margin8%(16%)(6%)8%
Net Profit$5M($8M)($5M)$5M
Net Margin6%(16%)(8%)6%

Financial data powered by Morningstar, Inc.

Sofwave Medical Stock Performance

Sofwave Medical has current market cap of $556M, and enterprise value of $523M.

Market Cap Evolution


Sofwave Medical's stock price is $15.39.

Sofwave Medical share price decreased by 5.9% in the last 30 days, and increased by 137.7% in the last year.

Sofwave Medical has an EPS (earnings per share) of $0.15.

See more trading valuation data for Sofwave Medical
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$523M$556M-3.5%-5.9%24.4%137.7%$0.15

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Sofwave Medical Valuation Multiples

Sofwave Medical trades at 6.0x EV/Revenue multiple, and 68.7x EV/EBITDA.

See NTM and 2027E valuation multiples for Sofwave Medical

Sofwave Medical Financial Valuation Multiples

As of June 4, 2026, Sofwave Medical has market cap of $556M and EV of $523M.

Sofwave Medical has a P/E ratio of 101.4x.

Last FY202320242025202620272028
EV/Revenue6.0x10.4x8.8x6.0x
EV/EBITDA68.7x(79.1x)(238.7x)68.7x
EV/EBIT76.2x(65.5x)(146.1x)76.2x
EV/Gross Profit7.9x14.0x11.5x7.9x
P/E101.4x(67.2x)(122.3x)101.4x
EV/FCF41.0x(77.9x)(195.7x)41.0x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Sofwave Medical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Sofwave Medical Margins & Growth Rates

In the most recent fiscal year, Sofwave Medical reported gross margin of 75%, EBITDA margin of 9%, and net margin of 6%.

See estimated margins and future growth rates for Sofwave Medical

Sofwave Medical Margins

Last FY20242025202720282029
Gross Margin75%76%75%
EBITDA Margin9%(4%)9%
EBIT Margin8%(6%)8%
Net Margin6%(8%)6%
FCF Margin15%(4%)15%

Sofwave Medical Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth19%47%
Gross Profit Growth21%45%
EBITDA Growth(67%)(447%)
EBIT Growth(55%)(292%)
Net Profit Growth(45%)(221%)
FCF Growth(60%)(577%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Sofwave Medical Operational KPIs

Access forward-looking KPIs for Sofwave Medical
Last FY202320242025202620272028
S&M Expenses to Revenue22%25%26%22%
G&A Expenses to Revenue3%3%6%3%
R&D Expenses to Revenue15%23%18%15%
Opex to Revenue67%90%82%67%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Sofwave Medical Competitors

Sofwave Medical competitors include NeuroPace, Japan Lifeline, Tactile Medical, Bioventus, Polynovo, Beta Bionics, Cytek Biosciences, Cerus, IBA Group and MiMedx Group.

Most Sofwave Medical public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
NeuroPace5.7x5.7x(114.3x)(86.6x)
Japan Lifeline1.4x1.3x5.8x5.6x
Tactile Medical1.4x1.4x10.6x10.1x
Bioventus1.4x1.3x6.8x6.7x
Polynovo5.9x5.0x72.0x57.2x
Beta Bionics3.8x3.3x(7.1x)(5.9x)
Cytek Biosciences1.5x1.5x(463.4x)(186.0x)
Cerus2.4x2.3x58.8x40.6x

This data is available for Pro users. Sign up to see all Sofwave Medical competitors and their valuation data.

Start Free Trial

Sofwave Medical VC Funding History

Before going public, Sofwave Medical raised $8M in total equity funding, across 1 round.


Sofwave Medical Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Aug-19Series AShimon Eckhouse; XT Venture Capital$8M-Sofwave Medical, an Israeli aesthetic medical company based in Yokneam, raised $8.4 million in a financing round in 2019 led by co-founder and chairman Shimon Eckhouse and XT Hi-Tech (also referred to as XT Venture Capital). The funds were intended to support aggressive execution on plans to build and position the company as a leader in the skin tightening market. The company develops non-invasive fractional ultrasound technology for skin tightening, wrinkle reduction, and skin revitalization using proprietary Synchronous Ultrasound Parallel Beam Technology (SUPERB). At the time, Sofwave had conducted a 60-person clinical study with U.S. dermatologists showing excellent results, no downtime, and an exceptional safety profile, which supported its 510(k) FDA submission. The company had also secured a CE Mark for commercialization outside the U.S. Concurrently, Louis Scafuri, former CEO of Syneron Candela, was appointed as CEO to lead global expansion in the fast-growing aesthetic medical device market.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Sofwave Medical

Where is Sofwave Medical headquartered?Sofwave Medical is headquartered in Israel.
Is Sofwave Medical publicly listed?Yes, Sofwave Medical is a public company listed on Tel Aviv Stock Exchange.
What is the stock symbol of Sofwave Medical?Sofwave Medical trades under SOFW ticker.
When did Sofwave Medical go public?Sofwave Medical went public in 2021.
Who are competitors of Sofwave Medical?Sofwave Medical main competitors include NeuroPace, Japan Lifeline, Tactile Medical, Bioventus, Polynovo, Beta Bionics, Cytek Biosciences, Cerus, IBA Group, MiMedx Group.
What is the current market cap of Sofwave Medical?Sofwave Medical's current market cap is $556M.
What is the current revenue of Sofwave Medical?Sofwave Medical's last fiscal year revenue is $88M.
What is the current EV/Revenue multiple of Sofwave Medical?Current revenue multiple of Sofwave Medical is 6.0x.
Is Sofwave Medical profitable?No, Sofwave Medical is not profitable.
How many companies Sofwave Medical has acquired to date?Sofwave Medical hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Sofwave Medical has invested to date?Sofwave Medical hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Sofwave Medical

Lists including Sofwave Medical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial